C. Lewden, D. Salmon, P. Morlat, S. Bevilacqua, and E. Jougla, Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS, International Journal of Epidemiology, vol.34, issue.1, pp.121-151, 2005.
DOI : 10.1093/ije/dyh307

E. Rosenthal, G. Pialoux, N. Bernard, C. Pradier, and D. Rey, Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study), Journal of Viral Hepatitis, vol.12, issue.3, pp.183-191, 2007.
DOI : 10.1016/S0140-6736(02)09411-4

D. Salmon-ceron, C. Lewden, P. Morlat, S. Bevilacqua, and E. Jougla, Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol, Journal of Hepatology, vol.42, issue.6, pp.799-805, 2005.
DOI : 10.1016/j.jhep.2005.01.022

R. Weber, C. Sabin, N. Friis-moller, P. Reiss, W. El-sadr et al., Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study, Arch Intern Med, vol.166, pp.1632-1673, 2006.

Y. Benhamou, M. Bochet, D. Martino, V. , C. F. Azria et al., Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients, Hepatology, vol.23, issue.4, pp.1054-1062, 1999.
DOI : 10.1002/hep.510300409

M. Ragni and S. Belle, Impact of Human Immunodeficiency Virus Infection on Progression to End???Stage Liver Disease in Individuals with Hemophilia and Hepatitis C Virus Infection, The Journal of Infectious Diseases, vol.183, issue.7, pp.1112-1117, 2001.
DOI : 10.1086/319273

F. Palella, . Jr, R. Baker, A. Moorman, J. Chmiel et al., Mortality in the Highly Active Antiretroviral Therapy Era, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.43, issue.1, pp.27-34, 2006.
DOI : 10.1097/01.qai.0000233310.90484.16

K. Petoumenos and M. Law, Risk factors and causes of death in the Australian HIV Observational Database, Sexual Health, vol.3, issue.2, pp.103-115, 2006.
DOI : 10.1071/SH05045

C. Sabin, C. Smith, M. Youle, F. Lampe, and D. Bell, Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers, AIDS, vol.20, issue.1, pp.67-71, 2006.
DOI : 10.1097/01.aids.0000196178.73174.24

J. Sackoff, D. Hanna, and M. Pfeiffer, Causes of Death among Persons with AIDS in the Era of Highly Active Antiretroviral Therapy: New York City, Annals of Internal Medicine, vol.145, issue.6, pp.397-406, 2006.
DOI : 10.7326/0003-4819-145-6-200609190-00003

M. Bongiovanni and F. Tordato, Steatohepatitis in HIV-Infected Subjects: Pathogenesis, Clinical Impact and Implications in Clinical Management, Current HIV Research, vol.5, issue.5, pp.490-498, 2007.
DOI : 10.2174/157016207781662407

P. Soentjens, B. Ostyn, S. Van-outryve, D. Ysebaert, and M. Vekemans, PORTAL VEIN THROMBOSIS IN A PATIENT WITH HIV TREATED WITH A PROTEASE INHIBITOR-CONTAINING REGIMEN, Acta Clinica Belgica, vol.81, issue.7, pp.24-33, 2006.
DOI : 10.1080/00365540310017014

F. Carrat, F. Bani-sadr, S. Pol, E. Rosenthal, F. Lunel-fabiani et al., Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>, JAMA, vol.292, issue.23, pp.2839-2887, 2004.
DOI : 10.1001/jama.292.23.2839

R. Chung, J. Andersen, P. Volberding, G. Robbins, T. Liu et al., Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons, New England Journal of Medicine, vol.351, issue.5, pp.451-460, 2004.
DOI : 10.1056/NEJMoa032653

M. Laguno, J. Murillas, J. Blanco, E. Martinez, and R. Miquel, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients, AIDS, vol.18, issue.13, pp.27-36, 2004.
DOI : 10.1097/00002030-200409030-00003

F. Torriani, M. Rodriguez-torres, J. Rockstroh, E. Lissen, and J. Gonzalez-garcia, Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients, New England Journal of Medicine, vol.351, issue.5, pp.438-50, 2004.
DOI : 10.1056/NEJMoa040842

C. Lewden, T. May, E. Rosenthal, C. Burty, F. Bonnet et al., Changes in causes of death among adults infected by the Human Immunodeficiency Virus (HIV) between, The Mortalit 2000 & 2005 surveys (ANRS EN19 and Mortavic, 2000.

N. Br-u-Ä, R. Fox, X. P. Marks, K. Naqvi, Z. Taylor et al., Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.???Canadian multicenter study, Journal of Hepatology, vol.47, issue.4, pp.527-564, 2007.
DOI : 10.1016/j.jhep.2007.06.010

J. Garcia-garcia, M. Romero-gomez, J. Giron-gonzalez, R. Rivera-irigoin, J. Torre-cisneros et al., Incidence of and Factors Associated with Hepatocellular Carcinoma among Hepatitis C Virus and Human Immunodeficiency Virus Coinfected Patients with Decompensated Cirrhosis, AIDS Research and Human Retroviruses, vol.22, issue.12, pp.1236-1277, 2006.
DOI : 10.1089/aid.2006.22.1236

N. Kontchou-'g, J. Paries, M. Htar, N. Ganne-carrie, L. Costentin et al., Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis, Clin Gastroenterol Hepatol, vol.4, pp.1062-1070, 2006.

L. Yu, D. Sloane, and C. Guo, Risk Factors for Primary Hepatocellular Carcinoma in Black and White Americans in 2000, Clinical Gastroenterology and Hepatology, vol.4, issue.3, pp.355-60, 2006.
DOI : 10.1016/j.cgh.2005.12.022

M. Nunez, B. Ramos, B. Diaz-pollan, N. Camino, L. Martin-carbonero et al., Virological Outcome of Chronic Hepatitis B Virus Infection in HIV-Coinfected Patients Receiving Anti-HBV Active Antiretroviral Therapy, AIDS Research and Human Retroviruses, vol.22, issue.9, pp.842-850, 2006.
DOI : 10.1089/aid.2006.22.842

V. Mallet, V. Dhalluin-venier, V. Verkarre, J. Correas, and M. Chaix, Viard JP Reversibility of cirrhosis in HIV/HBV coinfection, Antivir Ther, vol.12, pp.279-83, 2007.

G. Matthews, D. Cooper, and G. Dore, Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir, Antivir Ther, vol.12, pp.119-141, 2007.

I. Maida, M. Nunez, M. Rios, L. Martin-carbonero, G. Sotgiu et al., Severe Liver Disease Associated With Prolonged Exposure to Antiretroviral Drugs, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.42, issue.2, pp.177-82, 2006.
DOI : 10.1097/01.qai.0000221683.44940.62

V. Mallet, P. Blanchard, V. Verkarre, A. Vallet-pichard, and H. Fontaine, Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients, AIDS, vol.21, issue.2, pp.187-92, 2007.
DOI : 10.1097/QAD.0b013e3280119e47

P. Sandrine, A. Sylvie, E. Andre, D. Abdoulaye, L. Bernard et al., Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect?, AIDS, vol.21, issue.11, pp.1498-1507, 2007.
DOI : 10.1097/QAD.0b013e328235a54c

T. Schiano, D. Kotler, and E. Ferran, Hepatoportal Sclerosis as a Cause of Noncirrhotic Portal Hypertension in Patients With HIV, The American Journal of Gastroenterology, vol.63, issue.11, pp.2536-2576, 2007.
DOI : 10.1016/j.jhep.2005.07.006

I. Maida, P. Garcia-gasco, G. Sotgiu, M. Rios, and M. Vispo, Martin-Carbonero L Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome, Antivir Ther, vol.13, pp.103-110, 2008.

S. Deuffic-burban, T. Poynard, M. Sulkowski, and J. Wong, Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States, Journal of Viral Hepatitis, vol.54, issue.1, pp.107-122, 2007.
DOI : 10.1093/aje/154.7.675
URL : https://hal.archives-ouvertes.fr/hal-00199768

T. Powles, D. Macdonald, M. Nelson, and J. Stebbing, Hepatocellular cancer in HIV-infected individuals: tomorrow???s problem?, Expert Review of Anticancer Therapy, vol.6, issue.11, pp.1553-1561, 2006.
DOI : 10.1586/14737140.6.11.1553

V. Soriano, P. Labarga, A. Ruiz-sancho, J. Garcia-samaniego, and P. Barreiro, Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin, AIDS, vol.20, issue.17, pp.2225-2232, 2006.
DOI : 10.1097/01.aids.0000247583.38943.95

M. Nunez, C. Miralles, M. Berdun, E. Losada, K. Aguirrebengoa et al., Role of Weight-Based Ribavirin Dosing and Extended Duration of Therapy in Chronic Hepatitis C in HIV-Infected Patients: The PRESCO Trial, AIDS Research and Human Retroviruses, vol.23, issue.8, pp.972-82, 2007.
DOI : 10.1089/aid.2007.0011